A. 南京微創醫學科技有限公司 怎麼樣
聽說還行，還是自己看看
B. 中國醫療器械企業100強
1 遼寧愛母醫療科技有限公司
2 北京京精醫療設備有限公司
3 微創醫療器械(上海)有限公司
4 北京源德生物醫學工程有限公司
5 常州市武進第三醫療器械廠有限公司
6 北京博暉創新光電技術股份有限公司
7 上海愛培克電子科技有限公司
8 北京樂普醫療器械有限公司
9 廣州駿豐醫療器械有限公司
10 北京高特吸氣材料有限公司
11 山谷藍遠東國際醫療科技（北京）有限公司
12 佛山市中創醫療器械有限公司
13 上海菁華科技儀器有限公司
14 深圳市威爾德電子有限公司
15 武漢康橋醫學新技術有限公司
16 深圳市開立科技有限公司
17 北京周林頻譜科技有限公司
18 浙江巴奧米特醫葯產品有限公司
19 吉林領先科技發展股份有限公司
20 河北路德醫療器械有限公司
21 天津邁達醫學科技有限公司
22 深圳市清華源興納米醫葯科技有限公司
23 杭州好克光電儀器有限公司
24 上海安亭科學儀器廠
25 深圳市雷杜生命科學股份有限公司
26 福州昌暉自動化系統有限公司
27 深圳邁瑞生物醫療電子股份有限公司
28 北京普利生儀器有限公司
29 北京誼安美達科技發展有限公司
30 西安西京醫療用品有限公司
31 喜來健醫療器械有限公司
32 深圳市益心達醫學新技術有限公司
33 長春迪瑞實業有限公司
34 上海滬通電子有限公司
35 上海碩創生物醫葯科技有限公司
36 山西省榮軍假肢服務物中心
37 桂林高新區寶利泰醫療電子有限公司
38 北京航天中興醫療系統有限公司
39 北京伏爾特醫療器材科技有限公司
40 上海泰雷茲電子管有限公司
41 無錫祥生醫學影像有限公司
42 戴維醫療器械有限公司
43 大連庫利艾特醫療製品有限公司
44 北京昌航精鑄技術有限公司
45 深圳市科瑞康實業有限公司
46 煙台裕興紙製品有限公司
47 深圳市理邦精密儀器有限公司
48 杭州大力神醫療器械有限公司
49 樂陵市新諾醫療器械有限公司
50 美耐寶齒科（上海）有限公司
51 天津和傑醫療器械有限公司
52 北京萬東高星電子產品有限責任公司
53 上海徠卡儀器有限公司
54 浙江科惠醫療器材有限公司
55 上海市崇明縣明惠機械廠
56 柯頓（天津）電工電器有限公司
57 美敦力（上海）有限公司
58 北京市假肢矯形技術中心
59 博奧生物有限公司
60 廣東粵誠牙科技術開發中心
61 汕頭超聲儀器研究所
62 上海德爾格醫療器械有限公司
63 安丘奧宗麥克斯設備有限公司
64 福州迪肯醫療器械有限公司
65 東阿阿膠阿華醫療器械有限公司
66 天津市天堰醫教科技開發有限公司
67 深圳朗醫科技有限公司
68 山八齒材工業（常熟）有限公司
69 鄭州市新視明科技工程有限公司
70 熱電（上海）儀器有限公司
71 上海陸豐醫療器材有限公司
72 福建梅生醫療科技股份有限公司
73 成都江雪醫療器械有限公司
74 咸陽西北醫療器械集團有限公司
75 天津東華醫療系統有限公司
76 安徽養和醫療器械設備有限公司
77 綿陽立德電子技術有限公司
78 挪度醫療器械（蘇州）有限公司
79 新鄉市宇安醫用衛生材料有限公司
80 寧波佳恩生物科技有限公司
81 北京恆瑞美聯信息技術有限公司
82 北京達雅鼎醫療器械有限公司
83 四川省邁克科技有限責任公司
84 愛科來醫療電子（上海）有限公司
85 北京市康科瑞工程檢測技術有限責任公司
86 石家莊市滿友醫療器械實業有限公司
87 麗聲助聽器（福州）有限公司
88 北京四環科學儀器廠
89 上海三申醫療器械有限公司
90 北京三廣醫療器械有限公司
91 秦皇島康泰醫學系統有限公司
92 天津市中亞醫療科技開發有限公司
93 招遠市理療電器廠
94 鄭州市華盛醫療電器有限責任公司
95 北京橡果氧立得制氧有限公司
96 上海光電醫用電子儀器有限公司
97 湖北泰維醫療科技有限公司
98 南京普朗醫葯設備有限公司
99 上海同普放射防護設備有限公司
100 天津松華機電有限公司
C. 請大家幫忙翻譯這段話 謝謝
Introced on behalf of the enterprise
I, on behalf of the enterprise-based R & D outsourcing
Nanjing Chuanbo Biotechnology Co., Ltd. in August 2003 incorporated in the high-tech zones, with a registered capital of 12,000,000 yuan, is a Ph.D. from abroad and domestic scientists co-founder of the biotechnology business. Chuanbo to have a biological foreign experts and overseas students as the main body and doctorate or master's degrees composition of the technical backbone of the team. The company is committed to research and development of anti-antibody protein phosphorylation, after 3 years of research and development, has succeeded in building a development of the anti-protein phosphorylation antibody technology platform, has developed 17 kinds of cell signaling pathway in the 638 kinds of anti-phosphorylation Protein antibodies, 73 of which for the first time on the international success of the development of the antibody procts, procts have been sold in the United States, Canada, Britain, France, Germany and Japan more than 20 countries. Annual output value reached 125 million. Science and Technology Development Zone Company and established a joint venture center "of the Nanjing International Antibody Engineering Research Center," the company for long-term development strategy that antibody drug research platform for international cooperation.
Second, the proction of medical equipment on behalf of the enterprise
Minimally invasive Nanjing Medical Technology Co., Ltd. specializes in interventional stent lumen, a one-time sterile digestive endoscope, and so on endoscopic biopsy forceps the annex to the research and development of procts and proction sales. Own more than 10 patents, the Ministry of Health is "100 10-year plan to" bear the unit, China is the birthplace of the one-time biopsy forceps. The company has 1500 in line with the GMP requirements of 10,000 square meters clean workshop, is currently the only shop in the clean proction of the stent business. Company sales in 2007 amounted to 100,000,000 yuan.
Third, medicine, health procts on behalf of the proction-oriented enterprises
Kang Hae Medicine Co., Ltd. Nanjing (formerly Nanking Zhenzhong Biological Engineering Co., Ltd.), the main proct is Lentinan Nanjing in a row to support the eight years of their own intellectual property rights of high-tech procts. The procts have more than 80% of the domestic market, with an annual output capacity of 650,000, the output value reached 80,000,000 yuan. The other two companies - taxol liposomes and selegiline hydrochloride in the next two years will create a proction value of 50,000,000 yuan. The company is "Lentinan freeze-dried powder", "amifostine injection", "paclitaxel liposome components" has been an international PCT patent applications and has the United States, Japan, Russia, India, Thailand, the European Union Multi-national patent applications.
High-tech Zone of bioengineering and medicine instry with the times, the instry continues to prosper and grow in 2010 and bio-medical engineering science and technology park planning area will be 5.2 square kilometers, 200 enterprises to join in annual sales 20,000,000,000 yuan . Chinese medicine and bio-technology park for a leading innovation-driven, and increase input in research funding, to foster a number of market competitiveness and self-development capacity of the backbone of the new entity; at the same time establish and improve the research and development, pilot proction technology platform. With mice research advantage of the resources of the library resources, biological targeting information technology, biomedical engineering, gene therapy technology to carry out instrialization of research work, at home and abroad to introce genetic engineering-related fields of research and development institutions to further biomedical park in Nanjing to play the "three drug "Model Base of new drugs and the role of R & D base, to build a unique national biomedical research base.
Focus on the future development of the field
① biological information technology, bio-chip technology, biomedical engineering, gene therapy, cell therapy, such as the instrialization of research. Focus on the development of bio-informatics research and development platform, biological diagnostic chips, cellular immune therapy drugs, monoclonal antibody diagnostic reagents, genetic engineering drugs and vaccines and other procts.
② Chinese medicine and natural medicine quality standard certification technology; ingredient extraction, separation, purification, micro technology; active ingredients of Chinese medicine screening, the study of lead compounds, controlled-release technology of proprietary Chinese medicines, transdermal absorption of technology and targeted drug delivery technology And the development of Chinese medicine capsules, effervescent tablets, injections, pills, tablets, oral solution, and other new agents.
③ priority to the development of pharmaceutical chemical release, controlled release, targeted drug delivery technology and other modern technology. For cardiovascular disease, cancer, diabetes, autoimmune disease, kidney disease and hepatitis, multiple illnesses, development, with the introction of advanced technology at home and abroad of new drugs.